Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ernexa Therapeutics Inc.NTN · Entity 8278 | Director | August 30, 2019 | September 03, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ernexa Therapeutics Inc.
Report date August 30, 2019 · Filed September 03, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.43 · Expires 2029-08-29 | Direct | 600 |
Reported balance
After 2019-08-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-08-30 · Grant · Acquired 600 · Balance 600 F1: Stock option granted under the NTN Buzztime, Inc. 2019 Performance Incentive Plan. This option shall vest and become exercisable at the rate of 50% of the total number of shares covered by this option immediately upon the date of grant. The remaining 50% of the total number of shares covered by this option shall vest and become exercisable in 12 equal monthly installments beginning in the month immediately following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock option granted under the NTN Buzztime, Inc. 2019 Performance Incentive Plan. This option shall vest and become exercisable at the rate of 50% of the total number of shares covered by this option immediately upon the date of grant. The remaining 50% of the total number of shares covered by this option shall vest and become exercisable in 12 equal monthly installments beginning in the month immediately following the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 30, 2019 Filed Sep 3, 2019 22:00 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | GrantStock Options (Right to Buy) · Derivative | 600 | $0.00 Strike: $2.43 | $0.00 |
DisclosureSEC source: 0001493152-19-013635 · ownership.xml · derivative · entry 1 Miller Susan Elaine · CIK 0001785787 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600 Underlying: Common Stock · 600 shares Expires 2029-08-29 F1 · derivative.exercise_date: Stock option granted under the NTN Buzztime, Inc. 2019 Performance Incentive Plan. This option shall vest and become exercisable at the rate of 50% of the total number of shares covered by this option immediately upon the date of grant. The remaining 50% of the total number of shares covered by this option shall vest and become exercisable in 12 equal monthly installments beginning in the month immediately following the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.